Erratum: Clusterin decreases hepatic SREBP-1c expression and lipid accumulation (Endocrinology (2013) 154, (1722-1730) DOI: 10.1210/en.2012-2009);Clusterin decreases hepatic SREBP-1c expression and lipid accumulation

Endocrinology

Volumn 154, Issue 5, 2013, Pages 1722-1730

  Seo, Hye Young ^a   Kim, Mi Kyung ^a   Jung, Yun A ^a   Jang, Byoung Kuk ^a   Yoo, Eun Kyung ^b   Park, Keun Gyu ^b   Lee, In Kyu ^b  

^a Keimyung University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CLUSTERIN; LIVER X RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSCRIPTION FACTOR SP1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY LIVER; GENE OVEREXPRESSION; LIPID STORAGE; LIPOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM;

EID: 84876746246     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1388     Document Type: Erratum

References (35)

1. Targher G. Non-Alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med. 2007;24:1-6.
2. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndromeXin severe obesity. J Clin Endocrinol Metab. 1999; 84:1513-1517.
3. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118:829-838.
4. Deng X, Yellaturu C, Cagen L, et al. Expression of the rat sterol regulatory element-binding protein-1c gene in response to insulin is mediated by increased transactivating capacity of specificity protein 1 (Sp1). J Biol Chem. 2007;282:17517-17529.
5. Horton JD, Bashmakov Y, Shimomura I, Shimano H. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc Natl Acad Sci USA. 1998;95:5987-5992.
6. Horton JD. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem Soc Trans. 2002;30: 1091-1095.
7. Ferre P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 2010; 12(suppl 2):83-92.
8. Cagen LM, Deng X, Wilcox HG, Park EA, Raghow R, Elam MB. Insulin activates the rat sterol-regulatory-element-binding protein 1c (SREBP-1c) promoter through the combinatorial actions of SREBP, LXR, Sp-1 and NF-Y cis-Acting elements. Biochem J. 2005; 385:207-216.
9. Chen G, Liang G, Ou J, Goldstein JL, Brown MS. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci USA. 2004;101:11245-11250.
10. Schweizer M, Roder K, Zhang L, Wolf SS. Transcription factors acting on the promoter of the rat fatty acid synthase gene. Biochem Soc Trans. 2002;30:1070-1072.
11. Gelissen IC, Hochgrebe T, Wilson MR, et al Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-Atherogenic function? Biochem J. 1998;331(Pt 1): 231-237.
12. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol. 1995;27:633-645.
13. Gleave M, Jansen B. Clusterin and IGFBPs as antisense targets in prostate cancer. Ann NY Acad Sci. 2003;1002:95-104.
14. Wong P, Borst DE, Farber D, et al. Increased TRPM-2/clusterin mRNAlevels during the time of retinal degeneration in mouse models of retinitis pigmentosa. Biochem Cell Biol. 1994;72:439-446.
15. Witte DP, Aronow BJ, Stauderman ML, et al. Platelet activation releases megakaryocyte-synthesized apolipoprotein J, a highly abundant protein in atheromatous lesions. Am J Pathol. 1993;143: 763-773.
16. Miyata M, Biro S, Kaieda H, et al. Apolipoprotein J/clusterin is induced in vascular smooth muscle cells after vascular injury. Circulation. 2001;104:1407-1412.
17. StuartWD,Krol B, Jenkins SH, Harmony JA. Structure and stability of apolipoprotein J-containing high-density lipoproteins. Biochemistry. 1992;31:8552-8559.
18. de Silva HV, Stuart WD, Duvic CR, et al. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J Biol Chem. 1990;265:13240-13247.
19. Kim G, Kim GH, OH GS, et al. SREBP-1c regulates glucose-stimulated hepatic clusterin expression. Biochem Biophys ResCommun. 2011;408:720-725.
20. McLaughlin L, Zhu G, Mistry M, et al. Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. J Clin Invest. 2000;106:1105-1113.
21. Tarling E, Salter A, Bennett A. Transcriptional regulation of human SREBP-1c (sterol-regulatory-element-binding protein-1c): a key regulator of lipogenesis. Biochem Soc Trans. 2004;32:107-109.
22. Dif N, Euthine V, Gonnet E, Laville M, Vidal H, Lefai E. Insulin activates human sterol-regulatory-element-binding protein-1c (SREBP-1c) promoter through SRE motifs. Biochem J. 2006;400: 179-188.
23. Van Dijk A, Vermond RA, Krijnen PA, et al. Intravenous clusterin administration reduces myocardial infarct size in rats. Eur J Clin Invest. 2010;40:893-902.
24. Kim HJ, Yoo EK, Kim JY, et al. Protective role of clusterin/ apolipoprotein J against neointimal hyperplasia via antiproliferative effect on vascular smooth muscle cells and cytoprotective effect on endothelial cells. Arterioscler Thromb Vasc Biol. 2009;29:1558-1564.
25. Trougakos IP, Poulakou M, Stathatos M, Chalikia A, Melidonis A, Gonos ES. Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol. 2002;37:1175-1187.
26. Kujiraoka T, Hattori H, Miwa Y, et al. Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. J Atheroscler Thromb. 2006;13:314-322.
27. Hoofnagle AN, Wu M, Gosmanova AK, et al. Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia. Arterioscler Thromb Vasc Biol. 2010;30: 2528-2534.
28. DaimonM,Oizumi T, Karasawa S, et al. Association of the clusterin gene polymorphisms with type 2 diabetes mellitus. Metabolism. 2011;60:815-822.
29. Shimano H. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res. 2001;40:439-452.
30. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147-152.
31. Liu Q, Bengmark S, Qu S. The role of hepatic fat accumulation in pathogenesis of non-Alcoholic fatty liver disease (NAFLD). Lipids Health Dis. 2010;9:42.
32. Cuadrado A, Orive A, Garcia-Suarez C, et al. Non-Alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg. 2005;15:442-446.
33. MazzaA, Fruci B, GarinisGA,Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res. 2012;2012:716404.
34. Park KG, Min AK, Koh EH, et al. -Lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-Activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Hepatology. 2008;48:1477-1486.
35. Chen Z, Vigueira PA, Chambers KT, et al. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-Activated receptor -sparing thiazolidinedione. J Biol Chem. 2012;287:23537-23548.